- Record: found
- Abstract: found
- Article: not found
Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
Kristen Davis
1 ,
Sarah Wood
1 ,
Emily Dill
2 ,
Yuri Fesko
3 ,
Rhonda L Bitting
4 ,
Michael R Harrison
5 ,
Andrew J Armstrong
5 ,
Judd W Moul
5 ,
Daniel J George
5
Jun 2015
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Sipuleucel-T, an autologous cellular immunotherapy, is approved for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first personalized treatment for prostate cancer to be manufactured using the immune system of each individual patient. Patient preparation and compliance are critical because patients undergo serial leukapheresis and reinfusion procedures within a relatively short time period, which may result in transient reactions.